Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2010-01-05 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
第四届董事会第八次临时会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from Beijing Shuanglu Pharmaceutical Co., Ltd. regarding a resolution passed at the company's fourth board of directors' eighth extraordinary meeting. The content focuses on the approval of a stock option exercise by an incentive recipient, including details about the stock option plan, exercise conditions, and board approval. There is no financial statement or comprehensive financial data presented. The document is a board meeting resolution announcement related to management decisions on stock options, which fits the category of Board/Management Information (MANG). The document length is short (1071 characters), and it is not a report or a regulatory filing but a specific board decision announcement.
2010-01-05 Chinese
对外投资公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Beijing Shuanglu Pharmaceutical Co., Ltd. regarding an external investment in Nanjing Cavendish Bioengineering Technology Co., Ltd. It details the investment amount, purpose, risks, and impact on the company. The document includes information about the investment approval by the board, independent directors' opinions, and basic information about the investee company and its patents. There are no financial statements or comprehensive financial performance data. The document is a formal announcement of a capital investment transaction rather than a full financial report or earnings release. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is best classified as a Capital/Financing Update (CAP) because it concerns a significant investment and capital increase in another company.
2009-12-18 Chinese
第四届董事会第七次临时会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from the board of directors of Beijing SL Pharmaceutical Co., Ltd. regarding a resolution passed in a board meeting about investing in another company. It details the meeting date, voting results, and specifics of the investment. There is no financial report, earnings data, or regulatory certification. The content focuses on board decisions and management actions. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication, so it is not RPA. No other category fits better.
2009-12-18 Chinese
独立董事关于对外投资的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on an external investment decision made by the company. It discusses the board meeting approval of an investment in another company and provides the independent director's assessment of the fairness and compliance of the transaction. There are no financial statements, quarterly or annual results, or audit information presented. The document is a formal opinion related to a specific corporate action rather than a full report or announcement of financial results. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is also not a regulatory filing or announcement of voting results. The content aligns best with Board/Management Information (MANG) as it relates to board decisions and management-level investment approvals.
2009-12-18 Chinese
股权激励计划第二期行权情况暨股本变动公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from Beijing SL Pharmaceutical Co., Ltd. regarding the second phase of stock option exercise under its equity incentive plan. It details the number of stock options exercised, the exercise price, the qualifications of the incentive recipients, legal opinions, capital verification reports, changes in share capital structure, and lock-up periods. The document is focused on the company's stock option exercise event and related share capital changes, not a full financial report or earnings release. It is not a report publication announcement since it contains substantive details about the stock option exercise and capital changes. This fits the category of a Share Issue/Capital Change announcement, as it involves changes in share capital due to stock option exercises and related disclosures.
2009-12-03 Chinese
关于公司股票期权激励计划第二期行权相关事宜的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the second phase of stock option exercise under a stock option incentive plan of Beijing Shuanglu Pharmaceutical Co., Ltd. It discusses legal compliance, authorization, approval, and conditions related to the stock option exercise. The document is not a financial report, earnings release, or management discussion. It is a standalone legal opinion related to a specific corporate action (stock option exercise). This fits best under the category of Regulatory Filings (RNS) because it is a legal opinion letter related to regulatory compliance and corporate governance matters, not a full audit report or annual report. The document length (6876 characters) and content confirm it is not a brief announcement or a report publication announcement. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2009-12-03 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.